C L A I M S

1. A compound or polypeptide comprising at least one immunoglobulin single variable domain (ISVD),
wherein the at least one ISVD consists of SEQ ID NO: 40, with the proviso that
- the ISVD has an E instead of a D at position 1 of SEQ ID NO: 40 when the ISVD is not present at the N-terminal end of the compound or polypeptide; and
- the ISVD does not contain the C-terminal alanine of SEQ ID NO: 40 when the ISVD is not present at the C-terminal end of the compound or polypeptide.

2. The compound or polypeptide according to claim 1, wherein said compound or polypeptide further comprises a serum protein binding moiety, wherein said serum protein binding moiety binds serum albumin.

3. The compound or polypeptide according to claim 2, wherein said serum protein binding moiety is a serum albumin binding ISVD, and wherein said serum albumin binding ISVD essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which CDR1 is SFGMS, CDR2 is SISGSGSDTLYADSVKG and CDR3 is GGSLSR.

4. The compound or polypeptide according to claim 3, wherein said serum albumin binding ISVD is chosen from the group consisting of Alb8 (SEQ ID NO: 70), Alb23 (SEQ ID NO: 71), Alb129 (SEQ ID NO: 72), Alb132 (SEQ ID NO: 73), Alb11 (SEQ ID NO: 74), Alb11 (S112K)-A (SEQ ID NO: 75), Alb82 (SEQ ID NO: 76), Alb82-A (SEQ ID NO: 77), Alb82-AA (SEQ ID NO: 78), Alb82-AAA (SEQ ID NO: 79), Alb82-G (SEQ ID NO: 80), Alb82-GG (SEQ ID NO: 81), Alb82-GGG (SEQ ID NO: 82), Alb92 (SEQ ID NO: 83) and Alb223 (SEQ ID NO: 84).

5. A construct that comprises or essentially consists of the compound or polypeptide according to any one of claims 1-4, and which further comprises one or more other groups, residues, moieties or binding units, optionally linked via one or more peptidic linkers, in which said one or more other groups, residues, moieties or binding units is chosen from the group consisting of a polyethylene glycol molecule, serum proteins, binding units that can bind to serum proteins, an Fc portion, and small proteins or peptides that can bind to serum proteins.

6. A composition comprising the compound or polypeptide according to any one of claims 1-4 and/or the construct according to claim 5.

7. The composition according to claim 6, which is a pharmaceutical composition, which further comprises at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally comprises one or more further pharmaceutically active polypeptides and/or compounds.

8. The composition according to any one of claims 6-7, the construct according to claim 5, or the compound or polypeptide according to any one of claims 1-4 for use as a medicament.